CSS
PRVL

Cubist Systematic Strategies’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Cubist Systematic Strategies’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300
Closed -$3K – 2799
2020
Q3 		$3K Buy
+300
New +$4.03K ﹤0.01% 2458
2020
Q2 		– Sell
-5,323
Closed -$65K – 2599
2020
Q1 		$65K Buy
5,323
+3,847
+261% +$61.2K ﹤0.01% 1977
2019
Q4 		$23K Buy
+1,476
New +$18.8K ﹤0.01% 2339
2019
Q3 		– Sell
-17,425
Closed -$230K – 2614
2019
Q2 		$230K Buy
+17,425
New +$254K ﹤0.01% 1976

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's PRVL Position: Q4 2020 in Review

Cubist Systematic Strategies sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q4 2020, closing a stake of 300 shares — an estimated $3K sold.

Cubist Systematic Strategies first reported a position in PRVL in Q2 2019 and held it in 4 quarters. The position peaked at $230K in Q2 2019. 93 funds tracked by Wall St. Rank hold PRVL as of Q4 2020.

  • Cubist Systematic Strategies reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Cubist Systematic Strategies sold 300 Prevail Therapeutics Inc. Common Stock shares in Q4 2020, an estimated $3K.
  • Cubist Systematic Strategies first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Cubist Systematic Strategies's Prevail Therapeutics Inc. Common Stock position peaked at $230K in Q2 2019.
  • 93 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q4 2020.

Based on Cubist Systematic Strategies's 13F filing for Q4 2020, filed 16 Feb 2021.